Comparative Pharmacology
Head-to-head clinical analysis: BUDESONIDE versus PULMICORT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BUDESONIDE versus PULMICORT.
BUDESONIDE vs PULMICORT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Budesonide is a corticosteroid with potent glucocorticoid activity. It binds to the glucocorticoid receptor, leading to modulation of gene expression and suppression of inflammation by inhibiting pro-inflammatory cytokines and leukocyte migration.
Glucocorticoid receptor agonist; inhibits inflammatory mediators, reduces airway edema and mucus secretion.
Inhaled: 400-800 mcg/day in 2 divided doses for asthma; oral controlled ileal release: 9 mg once daily for Crohn's disease; intranasal: 256 mcg/day in 2 sprays per nostril once daily for allergic rhinitis.
Inhalation: 200-800 mcg twice daily for maintenance; maximum 1600 mcg/day. Nebulization: 0.5-1 mg twice daily.
None Documented
None Documented
Clinical Note
moderateBudesonide + Gatifloxacin
"The risk or severity of adverse effects can be increased when Budesonide is combined with Gatifloxacin."
Clinical Note
moderateBudesonide + Rosoxacin
"The risk or severity of adverse effects can be increased when Budesonide is combined with Rosoxacin."
Clinical Note
moderateBudesonide + Levofloxacin
"The risk or severity of adverse effects can be increased when Budesonide is combined with Levofloxacin."
Clinical Note
moderateBudesonide + Trovafloxacin
2-3.6 hours (terminal elimination half-life); due to high hepatic clearance, systemic half-life is short, limiting systemic exposure.
The terminal elimination half-life of budesonide is approximately 2.0 to 3.6 hours in adults, with a mean of about 2.8 hours. This short half-life is consistent with its rapid clearance and lack of significant accumulation with once- or twice-daily dosing.
Primarily hepatic metabolism via CYP3A4; metabolites excreted in feces (~60%) and urine (~10-15%). Renal excretion of unchanged drug is negligible (<2%).
Budesonide is primarily metabolized in the liver via CYP3A4 to inactive metabolites. Approximately 60% of the dose is excreted in urine as metabolites, and 40% in feces. Less than 10% of unchanged drug is excreted renally.
Category A/B
Category C
Inhaled Corticosteroid
Inhaled Corticosteroid
"The risk or severity of adverse effects can be increased when Budesonide is combined with Trovafloxacin."